High malignancy yield in core needle biopsy of BIRADS 3 breast lesions with calcification

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10568-10568
Author(s):  
A. Larke ◽  
A. O’Doherty ◽  
C. Quinn

10568 Background: Breast cancer screening programmes reduce mortality but result in increased numbers of breast biopsies. Stereotactic and ultrasound-guided core needle biopsy yield similar results to each other and to open biopsy. Study: Analysis of prospectively-acquired data relating to 174,338 screening mammograms performed in BreastCheck between Jan 2001 to Oct 2004. Relative use of ultrasound and stereotactic guidance for core needle biopsy is ascertained, and malignancy yields analysed. Results: In this time period, 174,338 screening mammograms discovered a total of 2782 lesions requiring further assessment. Of 2760 complete records, 1066 were BiRads R3–5 (39%) and 1033 of these (97%) had CNB. Guidance was provided exclusively by ultrasound in 737 (71%), and by stereotaxis in 270 (26%) of cases. There were no differences in malignancy yield of ultrasound versus sterotactically-guided CNB of R4 and R5 lesions (approximately 50% and 90% respectively). The malignancy yield in R3 lesions was significantly higher when performed with stereotactic guidance (12%) than when performed with ultrasound-guidance (5%) and both were significantly higher than R3 biopsy malignancy yields reported in the literature. Conclusion: Almost all BIRADS 3, 4 and 5 lesions are biopsied. The relatively high malignancy yield in R3 biopsies, particularly those with calcification, supports current practice. No significant financial relationships to disclose.

2020 ◽  
Vol 24 (06) ◽  
pp. 667-675
Author(s):  
Violeta Vasilevska Nikodinovska ◽  
Slavcho Ivanoski ◽  
Milan Samardziski ◽  
Vesna Janevska

AbstractBone and soft tissue tumors are a largely heterogeneous group of tumors. Biopsy of musculoskeletal (MSK) tumors is sometimes a challenging procedure. Although the open biopsy is still considered the gold standard for the biopsy of MSK lesions, core needle biopsy can replace it in most cases, with similar accuracy and a low complication rate. The biopsy should be performed in a tertiary sarcoma center where the multidisciplinary team consists of at minimum a tumor surgeon, an MSK pathologist, and an MSK radiologist who can assess all steps of the procedure. Several factors can influence the success of the biopsy including the lesion characteristics, the equipment, and the method used for the procedure. This review highlights some of the important aspects regarding the biopsy of the MSK tumors, with special attention to imaging a guided core needle biopsy and highlighting some of the recent advancements and controversies in the field.


2001 ◽  
Vol 17 (2) ◽  
pp. 113-122 ◽  
Author(s):  
Zita Morvay ◽  
Endre Szab?? ◽  
L??szl?? Tiszlavicz ◽  
J??zsef Fur??k ◽  
Imre Troj??n ◽  
...  

2003 ◽  
Vol 39 (14) ◽  
pp. 2021-2025 ◽  
Author(s):  
I. Ray-Coquard ◽  
D. Ranchère-Vince ◽  
P. Thiesse ◽  
H. Ghesquières ◽  
P. Biron ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document